

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

July 16, 2025

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for April 23, 2025, meeting
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/7-2025/April_2025_DURB_meeting_transcript_Post_State_review.pdf
- IV. Review of draft meeting summary for April 23, 2025, meeting (pages 4-8)
- V. Secretary's report (page 9)
- VI. Old Business
 - A. Utilization Trends of SGLT-2 inhibitors, GLP-1/GIP Agonists, and CGRP Inhibitors (pages 10-12)
 - B. Updated protocol for Attention Deficit Hyperactivity Disorder (ADHD) for Children <6 years old (pages 13-14)
 - C. Updated protocol for Spravato[®] (esketamine) (page 15)
- VII. New Business
 - A. Proposed addendum to the protocol for transthyretin-mediated Amyloidosis (ATTR) products (pages 16-18)
 - B. Proposed addendum to the protocol for Imcivree[®] (setmelanotide) (pages 19-21)
 - C. Proposed addendum to the protocol for Paroxysmal Nocturnal Hemoglobinuria (PNH) products (pages 22-24)
 - D. Proposed addendum to the protocol for Chimeric Antigen Receptor (CAR) T Cell Products (pages 25-30)
 - E. Proposed addendum to the protocol for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)/Glucose-Dependent-Insulinotropic-Polypeptide (GIP) Agonist for Type 2 Diabetes (pages 31-33)

VIII. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 1st Quarter 2025 Prior Authorization Report (page 34)
2. Summary of DURB Action Items (pages 35-39)
3. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category)

FFS top drugs:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2025/FFS_Top_Drugs_Report_April-2025.pdf

MCO top drugs:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2025/MCO_Top_Drugs_Report_March-2025.pdf

FFS top drugs by category:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2025/FFS_Top_Drugs_by_Category_April-2025.pdf

MCO top drugs by category:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2025/MCO_Top_Drugs_by_Category_March-2025.pdf

FFS antiviral drugs:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2025/FFS_Antiviral_Drugs_April-2025.pdf

B. Medication/Medical information

1. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systemic review and meta-analysis
[Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis - Berg - Obesity Reviews - Wiley Online Library](#)
2. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV – CDC Recommendations, United States, 2025

[Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025 | MMWR](#)

3. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline 2025
[Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline \(2025\) - American Urological Association](#)
4. Phase 3 Trial of Semaglutide in Metabolic Dysfunction – Associated Steatohepatitis
[Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine](#)